Matsuda Masaru

Matsuda Masaru sells 40,638 shares for $1,027,292.65 at ARQT; stock -13.6% in 30 days

Matsuda Masaru executed 4 separate sales totaling 40,638 shares for $1,027,292.65 on 2026-02-02, reducing his holdings by 27.0% from 150,641 to 110,003 shares. The sales occurred at prices ranging from $24.97 to $25.63 (blended average $25.28), slightly below the current price of $26.08 but ahead of the 30-day decline of -13.6%. His prior two buys at ARQT (2024-11-30 and 2024-05-31) both delivered strong 90-day returns of +99.8% and +550.1%, establishing a pattern of favorable entry timing at this ticker. The current sale coincides with a stock price that remains -16.4% from its 52-week high, despite the company's recent quarterly revenue of $99,219,000 and positive net income of $7,410,000, though full-year results remain unprofitable. This substantial reduction in position while the stock faces downward momentum warrants monitoring of underlying business catalysts and forward guidance.

Arcutis insider Matsuda Masaru purchased 5,657 shares across 2 transactions ($18,542.64 total); cluster buy pattern with 2 others in 14 days

Matsuda Masaru executed 2 separate purchases totaling 5,657 shares for $18,542.64, expanding his holdings from 181,373 shares to 187,030 shares (+3.1%). The buys occurred at notably different prices—4,000 shares at $1.69 on 2024-05-31 and 1,657 shares at $7.11 on 2024-11-30—reflecting significant volatility in the stock (52-week range $1.84–$13.04). A cluster pattern emerged with 2 other insiders also purchasing within 14 days of Matsuda's November transaction, suggesting coordinated or contextually motivated insider acquisition. ARQT generated $44.8M in revenue on a full-year net loss of $-41.5M, characteristic of an early-stage biotherapeutics company; the extreme annual revenue growth of +1517.1% indicates recent commercialization acceleration. The current price of $12.27 sits at -5.9% from the 52-week high and +41.5% above the 30-day average, showing recent strength but also elevated valuation relative to the purchase prices.